Background: Since SARS‐CoV‐2 infection was first identified in December 2019, the novel coronavirus‐induced pneumonia COVID‐19 spread rapidly and triggered a global pandemic. Recent bioinformatics evidence suggested that angiotensin‐converting enzyme 2—the main cell entry target of SARS‐CoV‐2—was predominantly enriched in spermatogonia, Leydig and Sertoli cells, which suggests the potential vulnerability of the male reproductive system to SARS‐CoV‐2 infection.Objectives: To identify SARS‐CoV‐2 RNA in seminal plasma and to determine semen characteristics from male patients in the acute and recovery phases of infection.Methods: From February 26 to April 2, 2020, 23 male patients with COVID‐19 were recruited. The clinical characteristics, laboratory findings and chest computed tomography scans of all patients were recorded in detail. We also investigated semen characteristics and the viral RNA load in semen from these patients in the acute and recovery phases of SARS‐CoV‐2 infection using approved methods.Results: The age range of the 23 patients was 20‐62 years. All patients tested negative for SARS‐CoV‐2 RNA in semen specimens. Among them, the virus had been cleared in 11 patients, as they tested negative. The remaining 12 patients tested negative for SARS‐CoV‐2 RNA in semen samples, but were positive in sputum and fecal specimens. The median interval from diagnosis to providing semen samples was 32 days, when total sperm counts, total motile sperm counts, and sperm morphology of the patients were within normal ranges.Discussion and Conclusion: In this cohort of patients with a recent infection or recovering from COVID‐19, there was no SARS‐CoV‐2 RNA detected in semen samples, which indicates the unlikely possibility of sexual transmission through semen at about 1 month after first detection.
Acute kidney injury (AKI) is sustained by reciprocal amplification of oxidative stress, innate immune signaling, and maladaptive immune–parenchymal crosstalk. Here, we developed a lipid nanoparticle containing a ceria nanozyme and a STING‐targeting CasRx plasmid and functionalized it with D4F, an 18‐residue apolipoprotein A‐I mimetic peptide composed of D‐amino acids. The resulting D4F‐CeO 2 @LNP‐CasRx(STING) formulation retained radical‐scavenging activity, supported CasRx encapsulation, and showed enhanced cellular and renal delivery. In macrophages, the formulation reduced oxidative stress and total STING abundance together with downstream TBK1 and IRF3 phosphorylation, shifted the CD86/CD206 profile toward a less inflammatory state, and altered the secretome in a manner that protected hypoxia‐challenged tubular epithelial cells. In kidney organoids and peripheral‐blood‐mononuclear‐cell‐coupled organoid cultures, D4F functionalization improved intratissue accumulation, increased the frequency of CD4 + FOXP3 + T cells, and attenuated the hypoxia‐associated DNA damage response and tubular injury. In mice with renal ischemia–reperfusion injury, treatment reduced STING signaling in CD11b + renal macrophages, improved renal function and histology, and lowered whole‐kidney inflammatory and injury readouts. Spatial transcriptomic and proteomic analyses were consistent with contraction of inflammatory immune states and restoration of repair‐associated programs. These findings support a DNA‐delivering nanozyme strategy for renal immune‐niche modulation in AKI.